Brookline Capital Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital analyst Kemp Dolliver has upgraded Oncternal Therapeutics (NASDAQ:ONCT) from Hold to Buy and set a price target of $2.

December 04, 2023 | 4:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncternal Therapeutics has been upgraded by Brookline Capital from Hold to Buy with a new price target of $2.
Upgrades by analysts typically lead to positive sentiment among investors and can result in a short-term increase in stock price. The new price target of $2 suggests a significant upside from the current trading price, assuming the stock is trading below this target.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100